GABAPENTIN | A075350 | ACTAVIS ELIZABETH LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition Amendment from Rising Pharma Holdings, Inc. FDA-2026-P-5123 · 6 docket documents Rising Pharma Holdings, Inc. filed this amendment to suitability petition FDA-2026-P-5123 on June 4, 2026, in response to an FDA information request seeking proposed product labeling for Gabapentin Capsules, 150 mg, pursuant to 21 CFR 314.93(d), which Rising submitted to support its ANDA filing for | Suitability | 2026-06-05 | Open | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0410
per ea
Lowest NADAC/Unit
$0.0210
per ea
Brand NDCs
0
Generic NDCs
8
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 45963055750GABAPENTIN 400 MG CAPSULE | $0.0410 | EA | Generic | — | 2026-06-17 |
| 45963055711GABAPENTIN 400 MG CAPSULE | $0.0410 | EA | Generic | — | 2026-06-17 |
| 45963055611GABAPENTIN 300 MG CAPSULE | $0.0324 | EA | Generic | — | 2026-06-17 |
| 00480349505GABAPENTIN 300 MG CAPSULE | $0.0324 | EA | Generic | — | 2026-06-17 |
| 45963055650GABAPENTIN 300 MG CAPSULE | $0.0324 | EA | Generic | — | 2026-06-17 |
| 45963055511GABAPENTIN 100 MG CAPSULE | $0.0210 | EA | Generic | — | 2026-06-17 |
| 45963055550GABAPENTIN 100 MG CAPSULE | $0.0210 | EA | Generic | — | 2026-06-17 |
| 00480349405GABAPENTIN 100 MG CAPSULE | $0.0210 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.